By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
OrthoSpineNews
  • Spine
  • Recon
  • Neuro
  • Extremities
  • Biologics
  • Sports Medicine
  • Robotics
  • Hospitals
  • Financial
  • Regulatory
  • Submit News / Advertise
Reading: Nanovis Announces Formation of Scientific Advisory Board to Advance FDA Designated Nanotechnology Surface
OrthoSpineNewsOrthoSpineNews
Font ResizerAa
Search
  • Spine
  • Recon
  • Neuro
  • Extremities
  • Biologics
  • Sports Medicine
  • Robotics
  • Hospitals
  • Financial
  • Regulatory
  • Submit News / Advertise
Have an existing account? Sign In
Follow US
© Foxiz News Network. Ruby Design Company. All Rights Reserved.
OrthoSpineNews > Recon > Nanovis Announces Formation of Scientific Advisory Board to Advance FDA Designated Nanotechnology Surface
ReconSpine

Nanovis Announces Formation of Scientific Advisory Board to Advance FDA Designated Nanotechnology Surface

Josh Sandberg
Last updated: 2023/11/03 at 9:52 AM
By Josh Sandberg 4 Min Read
Share
SHARE

The formation of the board comes at a pivotal time for Nanovis as they continue their ongoing mission to harness nanotechnology for enhanced patient care.

COLUMBIA CITY, Ind., Nov. 2, 2023 /PRNewswire-PRWeb/ — Nanovis, a leader in nanotechnology surface solutions for orthopedic, spinal, and dental applications, announces the formation of its Scientific Advisory Board (SAB). The board will include Dr. C. Lowry Barnes, Dr. Douglas W. Pahl, Dr. Brent Ponce, and Dr. Thomas J. Webster. This team is a multi-specialty, multi-disciplinary scientific advisory board comprising leaders across musculoskeletal specialties. Nanovis will continue to fill out their SAB in the coming months with other specialties such as dental, trauma, foot and ankle, and infectious disease.

Brian More, CEO of Nanovis, stated, “The formation of the SAB marks a pivotal moment for Nanovis in our ongoing mission to harness nanotechnology for enhanced patient care. The board’s collective expertise will be pivotal in advancing claims and indications for nanoVIS Ti Surface Technology, our FDA-designated nanotechnology surface that has been cleared on 7 product systems and successfully implanted in thousands of patients.”

Beyond technology advancement, the SAB will play a vital role in guiding Nanovis’ approach to clinical data collection and analysis. Their expertise will help strategize the collection of clinical data, guarantee its thorough examination, and assist in presenting the benefits of Nanovis’ technologies at conferences and in academic journals. This initiative aims to validate the clinical efficacy of the company’s surface technology portfolio, drive innovation, discover new product applications, and identify potential new markets.

Brian More added, “With the SAB’s guidance, we are well-positioned to break new ground in orthopedic implant technology, ensuring that our scientific breakthroughs translate to real-world benefits for surgeons and patients.”

Board Members:

Dr. C. Lowry Barnes

Orthopedic Surgeon

University Arkansas, Little Rock Chairman of Dept of Orthopedic Surgery Hip & Knee Specialty

Dr. Douglas W. Pahl

Orthopedic Surgeon

Hughston Spine and The Hughston Clinic Spine Specialty

Dr. Brent Ponce

Orthopedic Surgeon

Hughston Clinic, Columbus, GA

Chairman, Research at the Hughston Foundation Shoulder and Sports Medicine Specialty

Dr. Thomas J. Webster

Professor

Brown University

Division of Pre-college and Undergraduate Studies

Nanovis will be exhibiting its FDA-designated nanotechnology surface at the American Association of Hip and Knee Surgeons in Dallas, TX, from November 2-5, 2023. In combination with the AAHKS meeting, scientific advisory board member Dr. C. Lowry Barnes will be hosting a Nanovis-sponsored educational event on Nanotechnology in Total Joint Arthroplasty.

About Nanovis

Nanovis is a technology-driven company committed to discovering unmet clinical needs, developing innovative and enabling solutions, and validating new technologies for clinical and market acceptance. The company, through its subsidiary Nanovis Spine, has successfully commercialized its proprietary nanoVIS Ti Surface Technology™ across a range of spinal implants, including the nano FortiFix™ Pedicle Screws and Nano FortiCore™ PEEK Titanium Hybrid Interbodies, the latter being enriched with OsteoSync™ technology licensed from Sites Medical.

Notably, the nanoVIS Ti Surface Technology™ platform is showing potential in pre-clinical studies to evolve into an antimicrobial surface in select markets, while concurrently, Nanovis is innovating a next-generation antimicrobial technology aimed at combating localized infections across various applications, including skin, transcutaneous devices, and orthopedic implants.

Ready to learn more about the science behind nanoVIS Ti Surface Technology™? Join us on LinkedIn.

Media Contact

Guillaume Viallaneix, Nanovis, 1 (407) 960-2994, guillaume@medtechmomentum.com, MedTechMomentum.com

SOURCE Nanovis

You Might Also Like

AlloSource Announces First Implant of AceConnex™ Pre-Sutured Fascia Device in Hip Labral Reconstruction Procedure

Stratus® Medical adds fifth U.S. patent and two Canadian patents to its 29-patent global IP portfolio for the NIMBUS® Electrosurgical RF Multitined Expandable Electrode

Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan Adoption

Deputy Chief Executive Officer’s appointment

Dr. Gail Naughton, world-renowned authority in the multibillion-dollar regenerative medicine market, joins HippoFi as the Head of Regenerative Therapeutics and Commercialization

TAGGED: announces, nanotechnology, nanovis, Scientific Advisory Board
Share This Article
Facebook Twitter Email Copy Link Print

More Popular from Foxiz

ReconRegulatoryRobotics

Corin Group Attains 510(k) Clearance for Apollo™ Platform: Revolutionizing Robotic-Assisted Total Knee Arthroplasty

By Josh Sandberg 3 Min Read

FloSpine Revolutionizes Treatment for Spinal Stenosis with FDA Clearance of KeyLift™ System

By Josh Sandberg

Hello world!

By orthospinenews 0 Min Read
- Advertisement -
Ad image
ReconSports MedicineTop Stories

AlloSource Announces First Implant of AceConnex™ Pre-Sutured Fascia Device in Hip Labral Reconstruction Procedure

Pre-sutured fascia allograft designed for hip arthroscopists to help the surgeon increase their procedure efficiency and…

By Josh Sandberg
Financial

Zimmer Biomet Announces Third Quarter 2023 Financial Results

WARSAW, Ind., Nov. 7, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial…

By Josh Sandberg
SpineTop Stories

Deputy Chief Executive Officer’s appointment

Appointment of Sandrine Carleas Deputy Chief Executive Officer Ecully, November 7, 2023-The Spineway Group, a specialist…

By Josh Sandberg
FinancialHospitals

As Hospital ASC Development Continues to Accelerate, Health Systems are Seeking Larger Equity Stakes – Key Findings of 5th Avanza Intelligence Hospital Leadership ASC Survey

Survey available for download; podcast scheduled with further data analysis WESTCHESTER, Ill., Nov. 8, 2023 /PRNewswire/ -- Avanza…

By Josh Sandberg
Regulatory

Stratus® Medical adds fifth U.S. patent and two Canadian patents to its 29-patent global IP portfolio for the NIMBUS® Electrosurgical RF Multitined Expandable Electrode

MAGNOLIA, Texas, Nov. 8, 2023 /PRNewswire/ -- Stratus® Medical, a company focused on improving clinical outcomes for chronic pain…

By Josh Sandberg

Since 2006, OrthoSpine News has been the preferred source of news related to the Orthopedic, Spine, and Musculoskeletal markets for millions of readers.

Categories

  • Biologics
  • Extremities
  • Financial
  • Hospitals
  • Neuro
  • Recon
  • Regulatory
  • Robotics
  • Spine
  • Sports Medicine

Quick Links

  • Advertise with us
  • Newsletters

2024 OrthoSpine News. All Rights Reserved.

Join Us!

Subscribe to our newsletter and never miss the latest OrthoSpine News!

Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Lost your password?